AAI Warns FTC Of Impact Of Teva's $40.5B Generics Deal
The American Antitrust Institute took aim at Teva Pharmaceutical's planned $40.5 billion acquisition of Allergan's generics business in a letter to the Federal Trade Commission on Thursday, warning that the combination...To view the full article, register now.
Already a subscriber? Click here to view full article